Septerna, Inc. (SEPN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $23.47: Risk below floor (1.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.75; Negative price momentum.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule... Read more
Sell if holding. Engine safety override at $23.47: Risk below floor (1.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.75; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Volatile — 6.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.47: Risk below floor (1.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.75; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $22.10. Score 4.7/10, moderate confidence.
Take-profit target: $38.65 (+64.7% upside). Prior stop was $22.10. Stop-loss: $22.10.
Risk below floor (1.9 < 3.0); Value-trap signals (2/5): High leverage (D/E 3.8), Material insider selling (3 sells, 13.86% of cap).
Septerna, Inc. trades at a P/E of N/A (forward -12.1). TrendMatrix value score: 5.4/10. Verdict: Sell.
14 analysts cover SEPN with a consensus score of 4.1/5. Average price target: $44.
What does Septerna, Inc. do?Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral...
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.